drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Humanized IgG1 monoclonal antibody against EGFR/HER1 (ErbB1) that blocks ligand binding and receptor activation, inhibits downstream EGFR signaling, and may induce antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C2733
nci_thesaurus_preferred_term
Nimotuzumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Nimotuzumab binds to and inhibits EGFR, resulting in growth inhibition of tumor cells that overexpress EGFR. This agent may act synergistically with radiation therapy.
drug_mesh_term
Nimotuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting EGFR (HER1) that binds the extracellular domain to block ligand binding and receptor activation/dimerization, suppressing downstream EGFR signaling (RAS/RAF/MEK/ERK and PI3K/AKT) to inhibit tumor-cell proliferation and survival; may also mediate ADCC.
drug_name
Nimotuzumab
nct_id_drug_ref
NCT05978050